Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

Shanghai Conant Optical / Equity Bottom-Up

<ul>
<li>In 1H25, <a href="https://www.smartkarma.com/entities/shanghai-conant-optical-co-ltd" target="_blank" data-smartkarma-citation="entities:33004:1" rel="noopener">Shanghai Conant Optical (2276 HK)</a> reported revenue rise of 11% to RMB 1.1M buoyed by growth across segments like multifunctional lens (up 9%) and standardized lens (up 20%).</li>
<li>In 1H25, the company kept up with its consistency of expanding its gross margins period after period, as margin expanded from 39.2% in 1H24 to 41% in 1H25 (2024: 38.6%).</li>
<li>Shanghai Conant’s robust demand outlook, capacity expansion plans, R&amp;D initiatives and margin strength offer a strong long term secular growth story.</li>
</ul>


In 1H25, Shanghai Conant Optical (2276 HK) reported revenue rise of 11% to RMB 1.1M buoyed by growth across segments like multifunctional lens (up 9%) and standardized lens (up 20%).
In 1H25, the company kept up with its consistency of expanding its gross margins period after period, as margin expanded from 39.2% in 1H24 to 41% in 1H25 (2024: 38.6%).
Shanghai Conant’s robust demand outlook, capacity expansion plans, R&amp;D initiatives and margin strength offer a strong long term secular growth story.


Conant Optical (2276 HKG): Growth Optics Sharp & Clear with Expanding Margins, Robust Sales in 1H25

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Index Rebalance

<ul>
<li>We see 28 potential and close adds and 34 potential and close deletes for the Hang Seng Composite Index in September. Some of the stocks are close on market cap/liquidity.</li>
<li>A lot of the potential adds are very recently listed stocks that have a limited trading history. The low free float could lead to price spikes in the stocks.</li>
<li>There are stocks that have a very high percentage of holdings via Stock Connect and there could be some unwinding prior to the stocks becoming Sell-only.</li>
</ul>


We see 28 potential and close adds and 34 potential and close deletes for the Hang Seng Composite Index in September. Some of the stocks are close on market cap/liquidity.
A lot of the potential adds are very recently listed stocks that have a limited trading history. The low free float could lead to price spikes in the stocks.
There are stocks that have a very high percentage of holdings via Stock Connect and there could be some unwinding prior to the stocks becoming Sell-only.


HSCI Index Rebalance Preview and Stock Connect (Sep 2025): Plenty of Recent IPOs Could Be Added

<ul>
<li>
<a href="https://www.smartkarma.com/entities/shanghai-conant-optical-co-ltd" target="_blank" data-smartkarma-citation="entities:33004:1" rel="noopener">Shanghai Conant Optical (2276 HK)</a> to utilize proceeds from its January placement for the research, development, design and manufacturing of lenses and vision solutions for smart glasses and XR headsets.</li>
<li>The company will construct an automated RX resin lens production line with a focus on high-end customized lenses, at a cost of $4M, to be funded by internal accruals.</li>
<li>The company declared that based on the preliminary assessments, it expects its 1H25 net profit to increase by 30% mainly due to strong volume growth and higher ASP.</li>
</ul>



Shanghai Conant Optical (2276 HK) to utilize proceeds from its January placement for the research, development, design and manufacturing of lenses and vision solutions for smart glasses and XR headsets.
The company will construct an automated RX resin lens production line with a focus on high-end customized lenses, at a cost of $4M, to be funded by internal accruals.
The company declared that based on the preliminary assessments, it expects its 1H25 net profit to increase by 30% mainly due to strong volume growth and higher ASP.


Shanghai Conant Optical (2276 HKG): Lens of Strong Fundamentals Makes the Growth Optics Visible

Jiangsu Hengrui Pharmaceuticals / Index Rebalance

Jiangsu Hengrui Pharmaceuticals (1276 HK)

<ul>
<li>We see 21 potential and close adds and 34 potential and close deletes for the Hang Seng Composite Index in September. Some of the stocks are close on market cap/liquidity.</li>
<li>There have been some big listings in the last couple of months and those stocks should be added to the index in September. That increases the number of potential deletions.</li>
<li>There are stocks that have a very high percentage of holdings via Stock Connect and there could be some unwinding prior to the stocks becoming Sell-only.</li>
</ul>


We see 21 potential and close adds and 34 potential and close deletes for the Hang Seng Composite Index in September. Some of the stocks are close on market cap/liquidity.
There have been some big listings in the last couple of months and those stocks should be added to the index in September. That increases the number of potential deletions.
There are stocks that have a very high percentage of holdings via Stock Connect and there could be some unwinding prior to the stocks becoming Sell-only.


HSCI Index Rebalance Preview and Stock Connect: Potential Changes in September 2025

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Shanghai Conant Optical / Equity Capital Markets

<p>On April 1, 2021, <a href="https://www.smartkarma.com/entities/shanghai-conant-optical-co-ltd" target="_blank" data-smartkarma-citation="entities:33004:1" rel="noopener">Shanghai Conant Optical (SCO CH)</a> submitted its IPO prospectus to the Hong Kong Stock Exchange. Actually, <a href="https://www.smartkarma.com/entities/shanghai-conant-optics-co-a" target="_blank" data-smartkarma-citation="entities:8902:1" rel="noopener">Shanghai Conant Optics Co A (300061 CH)</a> became listed in the Shenzhen Stock Exchange in March 2010. At the time of listing, the Company enjoyed high reputation as the leading resin spectacle lens manufacturer in China and also had wide business exposure in the global market. However, after becoming a public company, the net profit attributed to shareholders of Conant Optical was RMB16 million in 2010 (down 25% YoY), RMB9.56 million in 2011 (down 40% YoY) and RMB(-840,000) in 2012 (down 109% YoY), decreasing for three consecutive years. So, how about Conant Optical after more than a decade? The following mainly analyzed the strength and concerns for the Company.</p>

On April 1, 2021, Shanghai Conant Optical (SCO CH) submitted its IPO prospectus to the Hong Kong Stock Exchange. Actually, Shanghai Conant Optics Co A (300061 CH) became listed in the Shenzhen Stock Exchange in March 2010. At the time of listing, the Company enjoyed high reputation as the leading resin spectacle lens manufacturer in China and also had wide business exposure in the global market. However, after becoming a public company, the net profit attributed to shareholders of Conant Optical was RMB16 million in 2010 (down 25% YoY), RMB9.56 million in 2011 (down 40% YoY) and RMB(-840,000) in 2012 (down 109% YoY), decreasing for three consecutive years. So, how about Conant Optical after more than a decade? The following mainly analyzed the strength and concerns for the Company.

Pre-IPO Shanghai Conant Optical - Here Are the Strength and the Concerns

China

Shanghai Conant Optical is a leading Chinese manufacturer of resin spectacle lenses, offering a wide range of standardized and customized lenses with various functionalities like polarization, photochromic, and blue-light blocking. The company also develops lenses and vision solutions for smart glasses and XR headsets. It was founded in 1996 and is headquartered in Shanghai, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Shanghai Conant Optical (2276 HK)

Conant Optical (2276 HKG): Growth Optics Sharp & Clear with Expanding Margins, Robust Sales in 1H25

Shanghai Conant Optical sees 11% revenue rise and consistent margin expansion in 1H25. Robust demand outlook, capacity expansion plans, and margin...

Tina Banerjee

HSCI Index Rebalance Preview and Stock Connect (Sep 2025): Plenty of Recent IPOs Could Be Added

The forecast adds to the index and Stock Connect are up 9.7% on average this month while the forecast deletes from the index and Stock Connect are...

Brian Freitas